1-5 of 5
William Gradishar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew J. Brenner, Alison Stopeck, Hannah Parris, Dexiang Gao, Tessa McSpadden, Jose Mayordomo, Jennifer R. Diamond, Peter Kabos, Virginia F. Borges
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5021–5030.
https://doi.org/10.1158/1078-0432.CCR-23-0117
Published: 15 December 2023
View article titled, Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
Open the PDF for Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer in another window
Includes: Supplementary data
Journal Articles

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen R.D. Johnston, Stephen K. Chia
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5172–5177.
https://doi.org/10.1158/1078-0432.CCR-20-0224
Published: 01 October 2020
View article titled, <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Open the PDF for <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials in another window
Includes: Supplementary data
Journal Articles

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis

Melinda L. Telli, Charles Chu, Sunil S. Badve, Shaveta Vinayak, Daniel P. Silver, Steven J. Isakoff, Virginia Kaklamani, William Gradishar, Vered Stearns, Roisin M. Connolly, James M. Ford, Joshua J. Gruber, Sylvia Adams, Judy Garber, Nadine Tung, Chris Neff, Ryan Bernhisel, Kirsten M. Timms, Andrea L. Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2704–2710.
https://doi.org/10.1158/1078-0432.CCR-19-0664
Published: 01 June 2020
View article titled, Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <em>BRCA1/2</em> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Open the PDF for Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <em>BRCA1/2</em> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis in another window
Journal Articles

Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Oukseub Lee, Megan E. Sullivan, Yanfei Xu, Chiara Rogers, Miguel Muzzio, Irene Helenowski, Ali Shidfar, Zexian Zeng, Hari Singhal, Borko Jovanovic, Nora Hansen, Kevin P. Bethke, Peter H. Gann, William Gradishar, J. Julie Kim, Susan E. Clare, Seema A. Khan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 25–34.
https://doi.org/10.1158/1078-0432.CCR-19-0443
Published: 03 January 2020
View article titled, Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Open the PDF for Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate in another window
Includes: Supplementary data
Journal Articles

Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer

Beatrice J. Edwards, Dennis W. Raisch, Veena Shankaran, June M. McKoy, William Gradishar, Andrew D. Bunta, Athena T. Samaras, Simone N. Boyle, Charles L. Bennett, Dennis P. West, Theresa A. Guise
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 560–568.
https://doi.org/10.1158/1078-0432.CCR-10-1595
Published: 01 February 2011
View article titled, Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
Open the PDF for Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer in another window